Hemoptysis
For hemoptysis resident survival guide, click here.
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Synonyms and keywords: Spitting up blood; bloody sputum; coughing up blood; blood in sputum; haemoptysis
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Lung has two main vascular systems that include pulmonary circulation and bronchial circulation. There are multiple anastomoses between pulmonary and bronchial arterieswhich create physiologic right to left shunts. Blood in the hemoptysis is mostly originated from the Lung. However, it could be from the gastrointestinal system as well. Primary origin of the blood comes from bronchial arteries. Hemoptysis is an important symptom that has different etiologies and pathogenesis mechanisms. Hemoptysis may happen following infarction and ischemia of pulmonaryparenchyma and vascular engorgement with erosion. Hemoptysis may be classified according to severity into 3 groups of mild, moderate, and massive bleeding. Life-threatening causes of hemoptysis include pulmonary embolism. Common causes of hemoptysis include bronchiectasis, acute respiratory tract infections, chronic obstructive pulmonary disease, bronchitis, pneumonia, lung cancer, tuberculosis, cystic fibrosis, and idiopathic.
Historical Perspective
During 129-199 A.D., Galen identified the bronchial arteries as internal vessels of the lung. Leonardo da Vinci illustrated lung circulation. In the 1960s, angiography of the thoracic aorta and bronchial tree was done. In 1963, angiography of bronchial arteries was described by Viramonte. In 1974, Remy introduced bronchial artery embolization(BAE) as a successful, effective, non-invasive procedure to treat hemoptysis.
Classification
Hemoptysis may be classified into several subtypes based on duration of symptoms, severity and origin of the bleeding. Based on the duration of symptoms, hemoptysis may be classified as either acute or chronic. Hemoptysis may be classified according to severity into 3 groups of mild, moderate, and massive bleeding. Based on the origin of bleeding, hemoptysis may be classified into two groups of pulmonary vs extrapulmonary bleeding.
Pathophysiology
Lung has two main vascular systems that include pulmonary circulation and bronchial circulation. There are multiple anastomoses between pulmonary and bronchial arterieswhich create physiologic right to left shunts. Blood in the hemoptysis is mostly originated from the Lung. However, it could be from the gastrointestinal system as well. Primary origin of the blood comes from bronchial arteries. However, other sources of bleeding might be pulmonary vessels, aorta, intercostal, coronary, thoracic, and phrenic arteries. Hemoptysis is an important symptom that has different etiologies and pathogenesis mechanisms. Hemoptysis may happen following infarction and ischemia of pulmonaryparenchyma as seen in pulmonary embolism, vasculitis, and infections. Another mechanism of hemoptysis is vascular engorgement with erosion as seen in bronchitis, bronchiectasis, and toxic exposure to cigarette and other irritants. In some cases underlying cause can not be identified and they are considered as idiopathic. However, they might present with massive hemoptysis. There are multiple conditions that are associated with hemoptysis which include granulomatosis with polyangiitis, sarcoidosis, immunodeficiency, and indoor ice hockey play.
Causes
Life-threatening causes of hemoptysis include pulmonary embolism. Common causes of hemoptysis include bronchiectasis, acute respiratory tract infections, chronic obstructive pulmonary disease, bronchitis, pneumonia, lung cancer, tuberculosis, cystic fibrosis, and idiopathic. Less common causes of hemoptysis include ruptured aneurysms, lung abscess, aspergilloma, idiopathic pulmonary fibrosis, behçet’s disease, aortobronchial fistula, pulmonary endometriosis, goodpasture syndrome, and foreign body aspiration.
Differentiating Hemoptysis from Other Diseases
Epidemiology and Demographics
The incidence of hemoptysis is approximately 100 per 100,000 individuals in the outpatient setting. There is no enough data on prevalence of hemoptysis. The mortality rate of patients with massive hemoptysis is approximately 50-100%, if left untreated. During 1995-2005, in-hospital mortality rate of massive hemoptysis was 0-15%. Patients of all age groups may develop hemoptysis. There is no racial predilection to hemoptysis. Hemoptysis affects men and women equally. Hemoptysis is a symptom that might affect everyone. Underlying causes of hemoptysis might be different in developed countries than in developing countries. In the United States, incidence of tuberculosis in patients with massive hemoptysis is 7%, while in south africa it is 85%.
Risk Factors
Common risk factors in the development of hemoptysis include cigarette smoking, chronic obstructive pulmonary disease, anticoagulant medications. Risk factors in the recurrence of hemoptysis include persistent residual mild bleeding following bronchial artery embolization, blood transfusion before the procedure, and aspergilloma. Less common risk factors in the development of hemoptysis include congestive heart failure and mitral regurgitation.
Screening
There is insufficient evidence to recommend routine screening for hemoptysis.
Natural History, Complications, and Prognosis
Hemoptysis is an important symptom that indicates an underlying pulmonary or extrapulmonary causes. Hemoptysis usually happens following bronchitis as an acute symptomand it resolves spontaneously or with antibiotic therapy within a week. Watchful observation in a patient with hemoptysis and normal chest x-ray is recommended. However, persistent and massive hemoptysis requires further investigations. Asphyxia and airway obstruction are common after massive hemoptysis. Prognosis of hemoptysis is generally excellent. However, massive hemoptysis has a poor prognosis and the mortality rate of patients with hemoptysis is approximately 50-100%, if left untreated.
Diagnosis
Diagnostic Study of Choice
The initial diagnostic study in a patient with hemoptysis is chest x-ray. If diagnosis is not found on chest x-ray, the next step is to perform high resolution CT scan or bronchoscopy. HRCT is better for diagnosis of bronchiectasis or lung carcinoma. Flexible bronchoscopy is better for diagnosis of mucosal abnormalities such as bronchitis, Dieulafoy disease or kaposi sarcoma.
History and Symptoms
Patients with hemoptysis may have a positive history of upper respiratory tract infection, gastrointestinal disease, exposure to patients with tuberculosis, bleeding disorders, medications (anticoagulants), and cigarette smoking. Common symptoms of hemoptysis include bloody sputum, chronic cough, shortness of breath, pleuritic chest pain, and wheezing. Less common symptoms of hemoptysis depends on the etiology include weight loss, change in cough, fatigue.
Physical Examination
Physical examination of patients with hemoptysis might be normal. However, patients might show different findings depend on underlying causes. Patients with hemoptysis usually appear anxious and depend on the severity of bleeding they might be critically ill. Patients with hemoptysis usually have abnormal vital signs indicating dehydration, other signs of mucosal bleeding, purulent bloody sputum, and abnormal lung exam indicating underlying pulmonary causes.
Laboratory Findings
There are laboratory tests that are helpful for diagnosis the underlying cause of hemoptysis. Sputum must be evaluated for the cytology, gram stain, culture, and acid-fast stain. Arterial blood gases might show hypoxia. Complete blood count (CBC) might show elevated WBC, low platelet, and anemia. Signs of dehydration might be detected in laboratorytests such as BUN, Cr, urinalysis, or electrolytes. Coagulation studies might be abnormal.
Electrocardiogram
There are no electrocardiogram findings associated with hemoptysis. However, electrocardiogram might be abnormal with some of the underlying causes of hemoptysis.
X-ray
Chest x-ray is the first diagnostic modality that is used in a patient with hemoptysis. Chest x-ray might differentiate underlying causes of hemoptysis. Chest x-ray is usually used to compare with previous or later imagings in order to evaluate the progression and resolution of the underlying cause. However, chest x-ray might be completely normal in patients with hemoptysis.
Echocardiography and Ultrasound
There are no echocardiography/ultrasound findings associated with hemoptysis. However, echocardiography or ultrasound might be abnormal with some of the underlying causes of hemoptysis.
CT scan
Chest CT scan and CT angiography may be helpful in the evaluation of a patient with hemoptysis. It is useful for assessing the cause of hemoptysis, localizing the origin of the blood, providing prognostic information by correlating between the extent of lobar involvement on high-resolution CT and the amount of bleeding, and assisting the interventional radiologist prior to treatment. CT scan is not helpful in unstable patients, patients with active bleeding who require bronchoscopy intervention, and patients with bilateral lung abnormalities.
MRI
Chest MRI may be helpful in the diagnosis of underlying causes of hemoptysis.
Other Imaging Findings
Other imaging findings may be helpful in the diagnosis of underlying causes of hemoptysis.
Other Diagnostic Studies
Rigid bronchoscopy may be helpful in the differentiating underlying etiologies of hemoptysis, localizing the bleeding site, identifying lung cancer, and even treatment of the underlying cause of hemoptysis in case of visible endoluminal lesions. Other diagnostic studies for localizing the site of bleeding in a patient with hemoptysis include angiographyand aortography.
Treatment
Medical Therapy
Hemoptysis is a symptom that indicates an underlying pulmonary or extrapulmonary cause. Pharmacologic medical therapy depends on an underlying cause. However, the mainstay of treatment for massive hemoptysis is supportive and surgical therapy.
Surgery
Massive hemoptysis is a life-threatening condition and requires prompt intensive care. Surgery is indicated in patients with hemoptysis who are resistant to embolization. Interventional techniques are used to stop bleeding which include bronchial arterial embolization, different bronchoscopic strategies such as cold saline lavage, topical vasoconstrictor agents, balloon tamponade, endobronchial stent placement, endobronchial spigot, oxidized regenerated cellulose, N-Butyl cyanoacrylate glue, fibrinogenthrombin, tranexamic acid, laser photocoagulation, argon plasma coagulation, and electrocautery. Surgical techniques that are used for management of hemoptysis include pulmonary resection, lobectomy, and bilobectomy. Surgical techniques are definitely curative, effective for localized lesions. However, surgery has a mortality rate of 10-30%. Currently, bronchial arterial embolization considered as a first line therapy for both new and recurrent hemoptysis.
Primary Prevention
Effective measures for the primary prevention of hemoptysis include smoking cessation, avoiding air pollutants, and use of physical barriers such as masks and gown.
Secondary Prevention
There are no established measures for the secondary prevention of hemoptysis.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
During 129-199 A.D., Galen identified the bronchial arteries as internal vessels of the lung. Leonardo da Vinci illustrated lung circulation. In the 1960s, angiography of the thoracic aorta and bronchial tree was done. In 1963, angiography of bronchial arteries was described by Viramonte. In 1974, Remy introduced bronchial artery embolization (BAE) as a successful, effective, non-invasive procedure to treat hemoptysis.
Historical Perspective
Discovery
- During 129-199 A.D., Galen identified the bronchial arteries as internal vessels of the lung.
- Leonardo da Vinci illustrated lung circulation.
- In the 1960s, angiography of the thoracic aorta and bronchial tree was done.[1]
- In 1963, angiography of bronchial arteries was described by Viramonte.[2]
Landmark Events in the Development of Treatment Strategies
- In 1974, Remy introduced bronchial artery embolization (BAE) as a successful, effective, non-invasive procedure to treat hemoptysis.[3]
References
- ↑ NEYAZAKI, Toshihiko (1962). “A Method for Arteriography of the Bronchial Artery”. Japanese Heart Journal. 3 (6): 523–536. doi:10.1536/ihj.3.523. ISSN 0021-4868.
- ↑ Viamonte, Manuel (1964). “Selective Bronchial Arteriography in Man”. Radiology. 83 (5): 830–839. doi:10.1148/83.5.830. ISSN 0033-8419.
- ↑ Ittrich, H.; Klose, H.; Adam, G. (2014). “Radiologic Management of Haemoptysis: Diagnostic and Interventional Bronchial Arterial Embolisation”. RöFo – Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 187 (04): 248–259. doi:10.1055/s-0034-1385457. ISSN 1438-9029.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Hemoptysis may be classified into several subtypes based on duration of symptoms, severity and origin of the bleeding. Based on the duration of symptoms, hemoptysis may be classified as either acute or chronic. Hemoptysis may be classified according to severity into 3 groups of mild, moderate, and massive bleeding. Based on the origin of bleeding, hemoptysis may be classified into two groups of pulmonary versus extrapulmonary bleeding.
Classification
- Hemoptysis may be classified into several subtypes based on:[1][2][3]
- Based on the severity of bleeding, hemoptysis may be classified as mild, moderate, and massive:[4][5][6][7]
| Category | Amount |
|---|---|
| Mild bleeding | <30 ml blood in 24 hours |
| Moderate bleeding | 30-200 ml blood in 24 hours |
| Massive bleeding | 200-600 ml blood in 24 hours |
References
- ↑ Fidan A, Ozdoğan S, Oruç O, Salepçi B, Ocal Z, Cağlayan B (2002). “Hemoptysis: a retrospective analysis of 108 cases”. Respir Med. 96 (9): 677–80. PMID 12243312.
- ↑ Noë, G.D.; Jaffé, S.M.; Molan, M.P. (2011). “CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment”. Clinical Radiology. 66 (9): 869–875. doi:10.1016/j.crad.2011.03.001. ISSN 0009-9260.
- ↑ Lee MK, Kim SH, Yong SJ, Shin KC, Kim HS, Yu TS, Choi EH, Lee WY (2015). “Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolization”. Clin Respir J. 9 (1): 53–64. doi:10.1111/crj.12104. PMID 24406077.
- ↑ Johnson JL (2002). “Manifestations of hemoptysis. How to manage minor, moderate, and massive bleeding”. Postgrad Med. 112 (4): 101–6, 108–9, 113. PMID 12400152.
- ↑ Mal H, Thabut G, Plantier L (2003). “[Hemoptysis]”. Rev Prat (in French). 53 (9): 975–9. PMID 12816036.
- ↑ Andersen PE (2006). “Imaging and interventional radiological treatment of hemoptysis”. Acta Radiol. 47 (8): 780–92. doi:10.1080/02841850600827577. PMID 17018424.
- ↑ Sakr L, Dutau H (2010). “Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management”. Respiration. 80 (1): 38–58. doi:10.1159/000274492. PMID 20090288.
- ↑ Yoon W, Kim JK, Kim YH, Chung TW, Kang HK (2002). “Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review”. Radiographics. 22 (6): 1395–409. doi:10.1148/rg.226015180. PMID 12432111.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Lung has two main vascular systems that include pulmonary circulation and bronchial circulation. There are multiple anastomoses between pulmonary and bronchial arteries which create physiologic right to left shunts. Blood in the hemoptysis is mostly originated from the Lung. However, it could be from the gastrointestinal system as well. Primary origin of the blood comes from bronchial arteries. However, other sources of bleeding might be pulmonary vessels, aorta, intercostal, coronary, thoracic, and phrenic arteries. Hemoptysis is an important symptom that has different etiologies and pathogenesis mechanisms. Hemoptysis may happen following infarction and ischemia of pulmonary parenchyma as seen in pulmonary embolism, vasculitis, and infections. Another mechanism of hemoptysis is vascular engorgement with erosion as seen in bronchitis, bronchiectasis, and toxic exposure to cigarette and other irritants. In some cases underlying cause can not be identified and they are considered as idiopathic. However, they might present with massive hemoptysis. There are multiple conditions that are associated with hemoptysis which include granulomatosis with polyangiitis, sarcoidosis, immunodeficiency, and indoor ice hockey play.
Pathophysiology
Physiology
- Lung has two main vascular systems that include pulmonary circulation and bronchial circulation.
- There are multiple anastomoses between pulmonary and bronchial arteries which create physiologic right to left shunts.
- Pulmonary circulation
- It provides gas exchange where deoxygenated blood enters the lungs through pulmonary arteries and oxygenated blood returns to circulation through pulmonary veins.
- Pulmonary arteries
- Pulmonary veins
- Pulmonary circulation


-
- Bronchial vessels provide blood and nutrients to the bronchi and connective tissue of the lungs. They supply blood to the respiratory bronchioles and the visceral pleura of the lung.
- Bronchial arteries carry oxygenated blood to the lung tissues. They are arised from the thoracic aorta. There are usually two branches to the left lung and one to the right lung.
- Bronchial veins return the deoxygenated blood from the lung tissues to the systemic circulation. The right side drains into the azygos vein and the left side drains into the left superior intercostal vein or the accessory hemiazygos vein.
{{#ev:youtube|K57qjYYjgIY}}
Pathogenesis
- Hemoptysis is an important symptom that has different etiologies and pathogenesis mechanisms.[3]
- Blood in the hemoptysis is mostly originated from the Lung. However, it could be from the gastrointestinal system as well.[4]
- Primary origin of the blood comes from bronchial arteries.[5][6]
- Other sources of bleeding might be:[7][8][6]
- Aorta
- Intercostal arteries
- Coronary arteries
- Thoracic arteries
- The upper and inferior phrenic arteries
- Pulmonary vessels
- Hemoptysis may happen following infarction and ischemia of pulmonary parenchyma. It is seen in following conditions:[9][10]
- Pulmonary emboli
- Vasculitis including:
- Infections including:
- Staphylococcus aureus
- Pseudomonas aeruginosa
- Aspergillus fumigatus
- The phycomycetes
- Another mechanism of hemoptysis is vascular engorgement with erosion. It is seen in following conditions:[11][12]
- Acute infection such as:
- Viral bronchitis
- Bacterial bronchitis
- Chronic infection such as:
- Toxic exposure
- Acute infection such as:
- In some cases underlying cause can not be identified and they are considered as idiopathic. However, they might present with massive hemoptysis.[13][14]
Associated Conditions
- There are multiple conditions that are associated with hemoptysis which include:
- Granulomatosis with polyangiitis
- Sarcoidosis
- Immunodeficiency
- Indoor ice hockey play[15][16]
References
- ↑ “File:2119 Pulmonary Circuit.jpg – Wikimedia Commons”.
- ↑ “File:Pulmonary Blood Circulation.png – Wikimedia Commons”.
- ↑ “Hemoptysis – Clinical Methods – NCBI Bookshelf”.
- ↑ Andersen, P. E. (2016). “Imaging and interventional radiological treatment of hemoptysis”. Acta Radiologica. 47 (8): 780–792. doi:10.1080/02841850600827577. ISSN 0284-1851.
- ↑ Ittrich, H.; Klose, H.; Adam, G. (2014). “Radiologic Management of Haemoptysis: Diagnostic and Interventional Bronchial Arterial Embolisation”. RöFo – Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 187 (04): 248–259. doi:10.1055/s-0034-1385457. ISSN 1438-9029.
- ↑ 6.0 6.1 Noë, G.D.; Jaffé, S.M.; Molan, M.P. (2011). “CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment”. Clinical Radiology. 66 (9): 869–875. doi:10.1016/j.crad.2011.03.001. ISSN 0009-9260.
- ↑ Sakr, L.; Dutau, H. (2010). “Massive Hemoptysis: An Update on the Role of Bronchoscopy in Diagnosis and Management”. Respiration. 80 (1): 38–58. doi:10.1159/000274492. ISSN 1423-0356.
- ↑ Gupta, Mudit; Srivastava, Deep Narayan; Seith, Ashu; Sharma, Sanjay; Thulkar, Sanjay; Gupta, Rashmi (2013). “Clinical Impact of Multidetector Row Computed Tomography Before Bronchial Artery Embolization in Patients With Hemoptysis: A Prospective Study”. Canadian Association of Radiologists Journal. 64 (1): 61–73. doi:10.1016/j.carj.2011.08.002. ISSN 0846-5371.
- ↑ Shigemura, Norihisa; Wan, Innes Y.; Yu, Simon C.H.; Wong, Randolph H.; Hsin, Michael K.Y.; Thung, Hoi K.; Lee, Tak-Wai; Wan, Song; Underwood, Malcolm J.; Yim, Anthony P.C. (2009). “Multidisciplinary Management of Life-Threatening Massive Hemoptysis: A 10-Year Experience”. The Annals of Thoracic Surgery. 87 (3): 849–853. doi:10.1016/j.athoracsur.2008.11.010. ISSN 0003-4975.
- ↑ Chun, Joo-Young; Morgan, Robert; Belli, Anna-Maria (2010). “Radiological Management of Hemoptysis: A Comprehensive Review of Diagnostic Imaging and Bronchial Arterial Embolization”. CardioVascular and Interventional Radiology. 33 (2): 240–250. doi:10.1007/s00270-009-9788-z. ISSN 0174-1551.
- ↑ Tom, Lisa M.; Palevsky, Harold I.; Holsclaw, Douglas S.; Trerotola, Scott O.; Dagli, Mandeep; Mondschein, Jeffrey I.; Stavropoulos, S. William; Soulen, Michael C.; Clark, Timothy W.I. (2015). “Recurrent Bleeding, Survival, and Longitudinal Pulmonary Function following Bronchial Artery Embolization for Hemoptysis in a U.S. Adult Population”. Journal of Vascular and Interventional Radiology. 26 (12): 1806–1813.e1. doi:10.1016/j.jvir.2015.08.019. ISSN 1051-0443.
- ↑ Zhao, Tian; Wang, Sini; Zheng, Lili; Jia, Zhongzhi; Yang, Yunjun; Wang, Weiping; Sun, Houzhang (2017). “The Value of 320-Row Multidetector CT Bronchial Arteriography in Recurrent Hemoptysis after Failed Transcatheter Arterial Embolization”. Journal of Vascular and Interventional Radiology. 28 (4): 533–541.e1. doi:10.1016/j.jvir.2017.01.006. ISSN 1051-0443.
- ↑ Savale L, Parrot A, Khalil A, Antoine M, Théodore J, Carette MF, Mayaud C, Fartoukh M (June 2007). “Cryptogenic hemoptysis: from a benign to a life-threatening pathologic vascular condition”. Am. J. Respir. Crit. Care Med. 175 (11): 1181–5. doi:10.1164/rccm.200609-1362OC. PMID 17332480.
- ↑ Herth F, Ernst A, Becker HD (November 2001). “Long-term outcome and lung cancer incidence in patients with hemoptysis of unknown origin”. Chest. 120 (5): 1592–4. PMID 11713139.
- ↑ Karlson-Stiber C, Höjer J, Sjöholm A, Bluhm G, Salmonson H (May 1996). “Nitrogen dioxide pneumonitis in ice hockey players”. J. Intern. Med. 239 (5): 451–6. PMID 8642238.
- ↑ “Exposure to nitrogen dioxide in an indoor ice arena – New Hampshire, 2011”. MMWR Morb. Mortal. Wkly. Rep. 61 (8): 139–42. March 2012. PMID 22377844.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Teresa Stahl, M.D. [2]; Sadaf Sharfaei M.D.[3]
Overview
Life-threatening causes of hemoptysis include pulmonary embolism. Common causes of hemoptysis include bronchiectasis, acute respiratory tract infections, chronic obstructive pulmonary disease, bronchitis, pneumonia, lung cancer, tuberculosis, cystic fibrosis, and idiopathic. Less common causes of hemoptysis include ruptured aneurysms, lung abscess, aspergilloma, idiopathic pulmonary fibrosis, behçet’s disease, aortobronchial fistula, pulmonary endometriosis, goodpasture syndrome, and foreign body aspiration.
Causes
Life Threatening Causes
- Hemoptysis may be a life-threatening condition depending on the severity of bleeding and must be treated appropriately.
- Life-threatening causes of hemoptysis include:
Common Causes
Less Common Causes
- Less common causes of hemoptysis include:[6][7]
- Ruptured aneurysms which include:
- Ruptured aortic aneurysm
- Ruptured bronchial artery aneurysm
- Ruptured pulmonary artery aneurysm
- Lung abscess
- Aspergilloma
- Idiopathic pulmonary fibrosis
- Behçet’s disease
- Aortobronchial fistula
- Ruptured aneurysms which include:
- Pulmonary endometriosis
Causes by Organ System
Causes in Alphabetical order
References
- ↑ Mal H, Thabut G, Plantier L (2003). “[Hemoptysis]”. Rev Prat (in French). 53 (9): 975–9. PMID 12816036.
- ↑ Allewelt M, Lode H (2005). “[Diagnosis of haemoptoe/haemoptysis]”. Dtsch. Med. Wochenschr. (in German). 130 (9): 450–2. doi:10.1055/s-2005-863074. PMID 15731957.
- ↑ Liippo K, Vasankari T (2011). “[Hemoptysis]”. Duodecim (in Finnish). 127 (2): 178–84. PMID 21442867.
- ↑ Ramírez Mejía AR, Méndez Montero JV, Vásquez-Caicedo ML, Bustos García de Castro A, Cabeza Martínez B, Ferreirós Domínguez J (2016). “Radiological Evaluation and Endovascular Treatment of Hemoptysis”. Curr Probl Diagn Radiol. 45 (3): 215–24. doi:10.1067/j.cpradiol.2015.07.007. PMID 26293972.
- ↑ Yazıcıoğlu A, Yekeler E, Yazıcı Ü, Aydın E, Taştepe İ, Karaoğlanoğlu N (2016). “Management of Massive Hemoptysis: Analyses of 58 Patients”. Turk Thorac J. 17 (4): 148–152. doi:10.5152/TurkThoracJ.2016.002. PMID 29404145.
- ↑ Noë, G.D.; Jaffé, S.M.; Molan, M.P. (2011). “CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment”. Clinical Radiology. 66 (9): 869–875. doi:10.1016/j.crad.2011.03.001. ISSN 0009-9260.
- ↑ Earwood JS, Thompson TD (2015). “Hemoptysis: evaluation and management”. Am Fam Physician. 91 (4): 243–9. PMID 25955625.
- ↑ name=”pmid9856693″>Ravishankar R, Samuels LE, Kaufman MS, Samuels FL, Thomas MP, Galindo L; et al. (1998). “Amiodarone-associated hemoptysis”. Am J Med Sci. 316 (6): 390–2. PMID 9856693.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid21150234″>Yiannakopoulou EC (2011). “Hemoptysis under diclofenac and antiplatelet doses of aspirin”. Pharmacology. 87 (1–2): 1–4. doi:10.1159/000321728. PMID 21150234.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid23410873″>Bouzelmat H, Chaib A, Kheyi J, Kotni M, Ghafir D, Moustaghfir A (2013). “[Hemoptysis revealing pulmonary artery aneurysm associated with intracardiac thrombosis: a delicate anticoagulation situation (a case report of Behçet’s disease)]”. J Mal Vasc. 38 (3): 198–200. doi:10.1016/j.jmv.2013.01.001. PMID 23410873.
- ↑ name=”pmid17368626″>Cho YJ, Murgu SD, Colt HG (2007). “Bronchoscopy for bevacizumab-related hemoptysis”. Lung Cancer. 56 (3): 465–8. doi:10.1016/j.lungcan.2007.01.022. PMID 17368626.
- ↑ name=”pmid18330760\”>Elbek O, Börekçi S, Dikensoy E, Kibar Y, Bayram H, Bakir K; et al. (2008). “Catamenial hemoptysis”. Tuberk Toraks. 56 (1): 87–91. PMID 18330760\ Check
|pmid=value (help). - ↑ name=”pmid1589607″>Perper JA, Van Thiel DH (1992). “Respiratory complications of cocaine abuse”. Recent Dev Alcohol. 10: 363–77. PMID 1589607.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid6830384″>Brandwein S, Esdaile J, Danoff D, Tannenbaum H (1983). “Wegener’s granulomatosis. Clinical features and outcome in 13 patients”. Arch Intern Med. 143 (3): 476–9. PMID 6830384.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid19364794″>Nanda S, Bhatt SP (2009). “Hereditary hemorrhagic telangiectasia: epistaxis and hemoptysis”. CMAJ. 180 (8): 838. doi:10.1503/cmaj.081003. PMC 2665967. PMID 19364794.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid16369404″>Sharma B, Sharma M, Bondi E, Sharma M (2005). “Kartagener’s syndrome associated with allergic bronchopulmonary aspergillosis”. MedGenMed. 7 (2): 25. PMC 1681543. PMID 16369404.
- ↑ name=”pmid19139613″>Alherabi A (2009). “A case of Lemierre syndrome”. Ann Saudi Med. 29 (1): 58–60. PMC 2813609. PMID 19139613.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid11753458″>Bjornson CL, Kirk VG (2001). “Munchausen’s syndrome presenting as hemoptysis in a 12-year-old girl”. Can Respir J. 8 (6): 439–42. PMID 11753458.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid2319524″>Kraus A, Guerra-Bautista G, Chavarria P (1990). “Paragonimiasis: an infrequent but treatable cause of hemoptysis in systemic lupus erythematosus”. J Rheumatol. 17 (2): 244–6. PMID 2319524.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid3430507″>Devogelaer JP, Pirson Y, Vandenbroucke JM, Cosyns JP, Brichard S, Nagant de Deuxchaisnes C (1987). “D-penicillamine induced crescentic glomerulonephritis: report and review of the literature”. J Rheumatol. 14 (5): 1036–41. PMID 3430507.
- ↑ name=”pmid11124658″>Drent M, Wessels S, Jacobs JA, Thijssen H (2000). “Association of diffuse alveolar haemorrhage with acquired vitamin K deficiency”. Respiration. 67 (6): 697. doi:56305 Check
|doi=value (help). PMID 11124658. - ↑ name=”pmid18273490″>Bédard E, Lopez S, Perron J, Houde C, Couture C, Vaillancourt R; et al. (2008). “Life-threatening hemoptysis following the Fontan procedure”. Can J Cardiol. 24 (2): 145–7. PMC 2644573. PMID 18273490.
- ↑ name=”pmid12857055″>Nakamori Y, Tominaga T, Inoue Y, Shinohara K (2003). “Propylthiouracil (PTU)-induced vasculitis associated with antineutrophil antibody against myeloperoxidase (MPO-ANCA)”. Intern Med. 42 (6): 529–33. PMID 12857055.
- ↑ name=”pmid18292723″>Iwata T, Inoue K, Nishiyama N, Izumi N, Mizuguchi S, Tsukioka T; et al. (2007). “Late massive hemoptysis after transbronchial biopsy of hamartoma: an involvement of pulmonary artery and vein”. Ann Thorac Cardiovasc Surg. 13 (6): 400–2. PMID 18292723.
- ↑ name=”pmid8200191″>Cahill BC, Ingbar DH (1994). “Massive hemoptysis. Assessment and management”. Clin Chest Med. 15 (1): 147–67. PMID 8200191.
- ↑ name=”pmid23651792″>Lee J, Park YS, Lee CH, Lee SM, Yoo CG, Kim YW; et al. (2013). “Antiplatelet or anticoagulant therapy might not increase the risk of haemoptysis in patients with bronchiectasis”. Int J Tuberc Lung Dis. 17 (7): 989–91. doi:10.5588/ijtld.12.0807. PMID 23651792.
Differentiating Hemoptysis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karina Zavaleta, MD [2], Anmol Pitliya, M.B.B.S. M.D.[3]
Cough with hemopotysis differential diagnosis
| Organ system | Diseases | Clinical manifestations | Diagnosis | Other features | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptoms | Physical exam | ||||||||||||||
| Onset | Duration | Productive cough | Hemoptysis | Weight lost | Fever | Dyspnea | Ascultation | Lab findings | Imaging | PFT | Gold standard | ||||
| Respiratory | Lower airway | Bronchiectasis[1] | Chronic |
|
+ Mucopurulent sputum | + | − | − | + |
|
|
|
| ||
| Foreing body aspiration[2][3][4] | Acute |
|
+ | + | − | + | + |
|
|
|
|
| |||
| Parenchyma | Lung cancer[5][6] | Chronic |
|
+ | + | + | +/− | + | The following investigations may be helpful: |
|
|
| |||
| Interstitial lung disease[7][8] | Chronic |
|
− | + | + | − | + |
|
The following investigations may be helpful: |
|
|
| |||
| Tuberculosis (TB)[9][10] | Chronic |
|
+ | + | + | + | + |
|
|
|
|
| |||
| Organ system | Diseases | Onset | Duration | Productive cough | Hemoptysis | Weight lost | Fever | Dyspnea | Ascultation | Lab findings | Imaging | PFT | Gold standard | Other features | |
| Cardiac | Mitral Stenosis[11][12] | Chronic |
|
+ Pink frothy | + | − | − | + |
|
|
|
|
|||
| Pulmonary hypertension[13][14] | Chronic |
|
− | + | + | − | + | The following investigations may be helpful: |
|
|
| ||||
| Autoimmune | Goodpasture syndrome[15][16] | Chronic |
|
− | + | − | − | + | The following investigations may be helpful:
|
|
|
||||
| Wegener’s disease (GPA) [17][18] | Chronic |
|
+ | + | + | + | + | The following investigations may be helpful: |
|
|
|
| |||
| Microscopic polyangitis (MPA)[19] | Chronic |
|
+ | + | + | + | + | The following investigations may be helpful:
|
|
|
|
| |||
| Churg−Strauss[20][21] | Chronic |
|
+ | + | + | + | + |
|
|
|
|
||||
References
- ↑ King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW (2006). “Characterisation of the onset and presenting clinical features of adult bronchiectasis”. Respir Med. 100 (12): 2183–9. doi:10.1016/j.rmed.2006.03.012. PMID 16650970.
- ↑ Hewlett JC, Rickman OB, Lentz RJ, Prakash UB, Maldonado F (2017). “Foreign body aspiration in adult airways: therapeutic approach”. J Thorac Dis. 9 (9): 3398–3409. doi:10.21037/jtd.2017.06.137. PMC 5708401. PMID 29221325.
- ↑ Rafanan AL, Mehta AC (2001). “Adult airway foreign body removal. What’s new?”. Clin. Chest Med. 22 (2): 319–30. PMID 11444115.
- ↑ Haddadi S, Marzban S, Nemati S, Ranjbar Kiakelayeh S, Parvizi A, Heidarzadeh A (2015). “Tracheobronchial Foreign-Bodies in Children; A 7 Year Retrospective Study”. Iran J Otorhinolaryngol. 27 (82): 377–85. PMC 4639691. PMID 26568942.
- ↑ Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). “Global cancer statistics”. CA Cancer J Clin. 61 (2): 69–90. doi:10.3322/caac.20107. PMID 21296855.
- ↑ Ost DE, Jim Yeung SC, Tanoue LT, Gould MK (2013). “Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines”. Chest. 143 (5 Suppl): e121S–e141S. doi:10.1378/chest.12-2352. PMC 4694609. PMID 23649435.
- ↑ Lama VN, Martinez FJ (2004). “Resting and exercise physiology in interstitial lung diseases”. Clin. Chest Med. 25 (3): 435–53, v. doi:10.1016/j.ccm.2004.05.005. PMID 15331185.
- ↑ Chetta A, Marangio E, Olivieri D (2004). “Pulmonary function testing in interstitial lung diseases”. Respiration. 71 (3): 209–13. doi:10.1159/000077416. PMID 15133338.
- ↑ Perlman DC, el-Sadr WM, Nelson ET, Matts JP, Telzak EE, Salomon N, Chirgwin K, Hafner R (1997). “Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG)”. Clin. Infect. Dis. 25 (2): 242–6. PMID 9332519.
- ↑ Barnes PF, Verdegem TD, Vachon LA, Leedom JM, Overturf GD (1988). “Chest roentgenogram in pulmonary tuberculosis. New data on an old test”. Chest. 94 (2): 316–20. PMID 2456183.
- ↑ MUNROE DS, RALLY CR (1963). “The diagnosis of mitral stenosis”. Can Med Assoc J. 88: 611–22. PMC 1921207. PMID 13936649.
- ↑ Chandrashekhar Y, Westaby S, Narula J (2009). “Mitral stenosis”. Lancet. 374 (9697): 1271–83. doi:10.1016/S0140-6736(09)60994-6. PMID 19747723.
- ↑ Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG (2011). “Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry”. Chest. 140 (1): 19–26. doi:10.1378/chest.10-1166. PMC 3198486. PMID 21393391.
- ↑ Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003). “Pulmonary function in primary pulmonary hypertension”. J Am Coll Cardiol. 41 (6): 1028–35. PMID 12651053.
- ↑ Boyce NW, Holdsworth SR (1986). “Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage”. Am. J. Kidney Dis. 8 (1): 31–6. PMID 3728460.
- ↑ Foster MH (2017). “Basement membranes and autoimmune diseases”. Matrix Biol. 57-58: 149–168. doi:10.1016/j.matbio.2016.07.008. PMC 5290253. PMID 27496347.
- ↑ Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992). “Wegener granulomatosis: an analysis of 158 patients”. Ann. Intern. Med. 116 (6): 488–98. PMID 1739240.
- ↑ Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DR, Jennette JC, Kallenberg CG, Luqmani R, Mahr AD, Matteson EL, Merkel PA, Specks U, Watts RA (2011). “Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis”. Arthritis Rheum. 63 (4): 863–4. doi:10.1002/art.30286. PMID 21374588.
- ↑ Jennette, J. Charles; Falk, Ronald J. (1997). “Small-Vessel Vasculitis”. New England Journal of Medicine. 337 (21): 1512–1523. doi:10.1056/NEJM199711203372106. ISSN 0028-4793.
- ↑ Vaglio A, Buzio C, Zwerina J (2013). “Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art”. Allergy. 68 (3): 261–73. doi:10.1111/all.12088. PMID 23330816.
- ↑ Lanham JG, Elkon KB, Pusey CD, Hughes GR (1984). “Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome”. Medicine (Baltimore). 63 (2): 65–81. PMID 6366453.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
The incidence of hemoptysis is approximately 100 per 100,000 individuals in the outpatient setting. There is no enough data on prevalence of hemoptysis. The mortality rate of patients with massive hemoptysis is approximately 50-100%, if left untreated. During 1995-2005, in-hospital mortality rate of massive hemoptysis was 0-15%. Patients of all age groups may develop hemoptysis. There is no racial predilection to hemoptysis. Hemoptysis affects men and women equally. Hemoptysis is a symptom that might affect everyone. Underlying causes of hemoptysis might be different in developed countries than in developing countries. In the United States, incidence of tuberculosis in patients with massive hemoptysis is 7%, while in south africa it is 85%.
Epidemiology and Demographics
Incidence
- The incidence of hemoptysis is approximately 100 per 100,000 individuals in the outpatient setting.[1]
Prevalence
- There is no enough data on prevalence of hemoptysis.
Case-fatality rate/Mortality rate
- The mortality rate of patients with massive hemoptysis is approximately 50-100%, if left untreated.[2][3]
- During 2000-2005, in-hospital mortality rate of massive hemoptysis was 0%.[4]
- During 1995-1999, in-hospital mortality rate of massive hemoptysis was 15%.[4]
Age
- Patients of all age groups may develop hemoptysis.
Race
- There is no racial predilection to hemoptysis.
Gender
- Hemoptysis affects men and women equally.
Region
- Hemoptysis is a symptom that might affect everyone.
Developed Countries
- Underlying causes of hemoptysis might be different in developed countries.
- In the United States, incidence of tuberculosis in patients with massive hemoptysis is 7%.[5]
Developing Countries
- Underlying causes of hemoptysis might be different in developing countries.
- In south africa, incidence of tuberculosis in patients with massive hemoptysis is 85%.[5]
References
- ↑ Jones, R.; Charlton, J.; Latinovic, R.; Gulliford, M. C (2009). “Alarm symptoms and identification of non-cancer diagnoses in primary care: cohort study”. BMJ. 339 (aug13 2): b3094–b3094. doi:10.1136/bmj.b3094. ISSN 0959-8138.
- ↑ Shigemura, Norihisa; Wan, Innes Y.; Yu, Simon C.H.; Wong, Randolph H.; Hsin, Michael K.Y.; Thung, Hoi K.; Lee, Tak-Wai; Wan, Song; Underwood, Malcolm J.; Yim, Anthony P.C. (2009). “Multidisciplinary Management of Life-Threatening Massive Hemoptysis: A 10-Year Experience”. The Annals of Thoracic Surgery. 87 (3): 849–853. doi:10.1016/j.athoracsur.2008.11.010. ISSN 0003-4975.
- ↑ Noë, G.D.; Jaffé, S.M.; Molan, M.P. (2011). “CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment”. Clinical Radiology. 66 (9): 869–875. doi:10.1016/j.crad.2011.03.001. ISSN 0009-9260.
- ↑ 4.0 4.1 Sakr, L.; Dutau, H. (2010). “Massive Hemoptysis: An Update on the Role of Bronchoscopy in Diagnosis and Management”. Respiration. 80 (1): 38–58. doi:10.1159/000274492. ISSN 1423-0356.
- ↑ 5.0 5.1 Earwood JS, Thompson TD (2015). “Hemoptysis: evaluation and management”. Am Fam Physician. 91 (4): 243–9. PMID 25955625.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Common risk factors in the development of hemoptysis include cigarette smoking, chronic obstructive pulmonary disease, anticoagulant medications. Risk factors in the recurrence of hemoptysis include persistent residual mild bleeding following bronchial artery embolization, blood transfusion before the procedure, and aspergilloma. Less common risk factors in the development of hemoptysis include congestive heart failure and mitral regurgitation.
Risk Factors
- Common risk factors in the development of hemoptysis include:[1][2][3]
- Risk factors in the recurrence of hemoptysis include:[4]
- Persistent residual mild bleeding following bronchial artery embolization
- Blood transfusion before the procedure
- Aspergilloma
- Less common risk factors in the development of hemoptysis include:
References
- ↑ Lee, Myoung Kyu; Kim, Sang-Ha; Yong, Suk Joong; Shin, Kye Chul; Kim, Hyun Sik; Yu, Tae-Sun; Choi, Eun Hee; Lee, Won-Yeon (2015). “Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolization”. The Clinical Respiratory Journal. 9 (1): 53–64. doi:10.1111/crj.12104. ISSN 1752-6981.
- ↑ Khalil, A.; Fedida, B.; Parrot, A.; Haddad, S.; Fartoukh, M.; Carette, M.-F. (2015). “Severe hemoptysis: From diagnosis to embolization”. Diagnostic and Interventional Imaging. 96 (7–8): 775–788. doi:10.1016/j.diii.2015.06.007. ISSN 2211-5684.
- ↑ Bruzzi, John F.; Rémy-Jardin, Martine; Delhaye, Damien; Teisseire, Antoine; Khalil, Chadi; Rémy, Jacques (2006). “Multi–Detector Row CT of Hemoptysis”. RadioGraphics. 26 (1): 3–22. doi:10.1148/rg.261045726. ISSN 0271-5333.
- ↑ Sakr, L.; Dutau, H. (2010). “Massive Hemoptysis: An Update on the Role of Bronchoscopy in Diagnosis and Management”. Respiration. 80 (1): 38–58. doi:10.1159/000274492. ISSN 1423-0356.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for hemoptysis.
Screening
There is insufficient evidence to recommend routine screening for hemoptysis.
References
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Hemoptysis is an important symptom that indicates an underlying pulmonary or extrapulmonary causes. Hemoptysis usually happens following bronchitis as an acute symptom and it resolves spontaneously or with antibiotic therapy within a week. Watchful observation in a patient with hemoptysis and normal chest x-ray is recommended. However, persistent and massive hemoptysis requires further investigations. Asphyxia and airway obstruction are common after massive hemoptysis. Prognosis of hemoptysis is generally excellent. However, massive hemoptysis has a poor prognosis and the mortality rate of patients with hemoptysis is approximately 50-100%, if left untreated.
Natural History, Complications, and Prognosis
Natural History
- Hemoptysis is an important symptom that indicates an underlying pulmonary or extrapulmonary causes.[1][2]
- Hemoptysis usually happens following bronchitis as an acute symptom and it resolves spontaneously or with antibiotic therapy within a week.[3]
- Watchful observation in a patient with hemoptysis and normal chest x-ray is recommended.
- Patients with warning signs must be investigated. Warning signs are as follow:[4][5]
- Persistent hemoptysis more than one week
- Chest pain
- Weight loss
- Night sweats
- Fever higher than 101 degrees
- Shortness of breath
- Change in cough
- Fatigue
Complications
- Common complications of massive hemoptysis include:[6][7]
- Complications after bronchial artery embolization include:[8][9][10]
- Spinal cord injury
- Esophageal ulcer
- Stroke
- Bronchial infarction
- Transient chest pain
Prognosis
- Prognosis of hemoptysis is generally excellent. However, it requires further investigations.[3]
- Massive hemoptysis has a poor prognosis and the mortality rate of patients with hemoptysis is approximately 50-100%, if left untreated.[11][12]
References
- ↑ Corey R. Hemoptysis. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 39. Available from: https://www.ncbi.nlm.nih.gov/books/NBK360/
- ↑ Lee, Yeon Joo; Lee, Sang-Min; Park, Jong Sun; Yim, Jae-Joon; Yang, Seok-Chul; Kim, Young Whan; Han, Sung Koo; Lee, Jae Ho; Lee, Choon-Taek; Yoon, Ho Il; Yoo, Chul-Gyu (2012). “The clinical implications of bronchoscopy in hemoptysis patients with no explainable lesions in computed tomography”. Respiratory Medicine. 106 (3): 413–419. doi:10.1016/j.rmed.2011.11.010. ISSN 0954-6111.
- ↑ 3.0 3.1 Lee, Myoung Kyu; Kim, Sang-Ha; Yong, Suk Joong; Shin, Kye Chul; Kim, Hyun Sik; Yu, Tae-Sun; Choi, Eun Hee; Lee, Won-Yeon (2015). “Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolization”. The Clinical Respiratory Journal. 9 (1): 53–64. doi:10.1111/crj.12104. ISSN 1752-6981.
- ↑ Khalil, A.; Fedida, B.; Parrot, A.; Haddad, S.; Fartoukh, M.; Carette, M.-F. (2015). “Severe hemoptysis: From diagnosis to embolization”. Diagnostic and Interventional Imaging. 96 (7–8): 775–788. doi:10.1016/j.diii.2015.06.007. ISSN 2211-5684.
- ↑ Jones, Roger; Latinovic, Radoslav; Charlton, Judith; Gulliford, Martin C (2007). “Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database”. BMJ. 334 (7602): 1040. doi:10.1136/bmj.39171.637106.AE. ISSN 0959-8138.
- ↑ Dweik RA, Stoller JK (1999). “Role of bronchoscopy in massive hemoptysis”. Clin. Chest Med. 20 (1): 89–105. PMID 10205720.
- ↑ Allewelt M, Lode H (2005). “[Diagnosis of haemoptoe/haemoptysis]”. Dtsch. Med. Wochenschr. (in German). 130 (9): 450–2. doi:10.1055/s-2005-863074. PMID 15731957.
- ↑ Andersen, P. E. (2016). “Imaging and interventional radiological treatment of hemoptysis”. Acta Radiologica. 47 (8): 780–792. doi:10.1080/02841850600827577. ISSN 0284-1851.
- ↑ Gupta, Mudit; Srivastava, Deep Narayan; Seith, Ashu; Sharma, Sanjay; Thulkar, Sanjay; Gupta, Rashmi (2013). “Clinical Impact of Multidetector Row Computed Tomography Before Bronchial Artery Embolization in Patients With Hemoptysis: A Prospective Study”. Canadian Association of Radiologists Journal. 64 (1): 61–73. doi:10.1016/j.carj.2011.08.002. ISSN 0846-5371.
- ↑ Kalva, Sanjeeva P. (2009). “Bronchial Artery Embolization”. Techniques in Vascular and Interventional Radiology. 12 (2): 130–138. doi:10.1053/j.tvir.2009.08.006. ISSN 1089-2516.
- ↑ Shigemura, Norihisa; Wan, Innes Y.; Yu, Simon C.H.; Wong, Randolph H.; Hsin, Michael K.Y.; Thung, Hoi K.; Lee, Tak-Wai; Wan, Song; Underwood, Malcolm J.; Yim, Anthony P.C. (2009). “Multidisciplinary Management of Life-Threatening Massive Hemoptysis: A 10-Year Experience”. The Annals of Thoracic Surgery. 87 (3): 849–853. doi:10.1016/j.athoracsur.2008.11.010. ISSN 0003-4975.
- ↑ Noë, G.D.; Jaffé, S.M.; Molan, M.P. (2011). “CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment”. Clinical Radiology. 66 (9): 869–875. doi:10.1016/j.crad.2011.03.001. ISSN 0009-9260.
Diagnosis
Diagnosis
Diagnostic Study of Choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
